Annovis Bio Net Worth
Annovis Bio Net Worth Breakdown | ANVS |
Annovis Bio Net Worth Analysis
Annovis Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Annovis Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Annovis Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Annovis Bio's net worth analysis. One common approach is to calculate Annovis Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Annovis Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Annovis Bio's net worth. This approach calculates the present value of Annovis Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Annovis Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Annovis Bio's net worth. This involves comparing Annovis Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Annovis Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Annovis Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Annovis Bio's net worth research are outlined below:
| Annovis Bio generated a negative expected return over the last 90 days | |
| Annovis Bio has high historical volatility and very poor performance | |
| Annovis Bio may become a speculative penny stock | |
| Annovis Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (56.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annovis Bio currently holds about 35.97 M in cash with (39.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Annovis Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Annovis Joins Experts at Drug Development Summit to Redefine Parkinsons Treatment |
Annovis Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Annovis Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Annovis Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Annovis Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Annovis Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Annovis Bio backward and forwards among themselves. Annovis Bio's institutional investor refers to the entity that pools money to purchase Annovis Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-12-31 | 32.8 K | Greenwich Wealth Management Llc | 2024-12-31 | 32 K | Group One Trading, Lp | 2024-12-31 | 26.2 K | Sterling Investment Advisors Ltd | 2024-12-31 | 24 K | Bridgeway Capital Management, Llc | 2024-12-31 | 21.4 K | Spears Abacus Advisors Llc | 2024-12-31 | 20 K | Bank Of New York Mellon Corp | 2024-12-31 | 19.1 K | Lokken Investment Group Llc | 2024-12-31 | 18.2 K | Atria Wealth Solutions, Inc. | 2024-12-31 | 13 K | Vanguard Group Inc | 2024-12-31 | 466.3 K | Citadel Advisors Llc | 2024-12-31 | 215.2 K |
Follow Annovis Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.32 M.Market Cap |
|
Project Annovis Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.96) | (5.20) | |
| Return On Capital Employed | (8.73) | (8.30) | |
| Return On Assets | (4.96) | (5.20) | |
| Return On Equity | 6.53 | 6.85 |
When accessing Annovis Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Annovis Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Annovis Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Check Annovis Bio's Beneish M Score to see the likelihood of Annovis Bio's management manipulating its earnings.
Evaluate Annovis Bio's management efficiency
Annovis Bio has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 6.85 in 2025, whereas Return On Tangible Assets are likely to drop (5.20) in 2025. At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2025, whereas Return On Tangible Assets are likely to drop (5.20) in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.77) | (0.73) | |
| Tangible Book Value Per Share | (0.77) | (0.73) | |
| Enterprise Value Over EBITDA | (4.16) | (3.95) | |
| Price Book Value Ratio | (25.03) | (23.78) | |
| Enterprise Value Multiple | (4.16) | (3.95) | |
| Price Fair Value | (25.03) | (23.78) | |
| Enterprise Value | 73.1 M | 44.9 M |
The leadership approach at Annovis Bio's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Annovis Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Annovis Bio time-series forecasting models is one of many Annovis Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Annovis Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Annovis Bio Earnings per Share Projection vs Actual
Annovis Bio Corporate Management
| Blake Jensen | Head Quality | Profile | |
| Reid McCarthy | Independent Director | Profile | |
| Cheng Fang | Senior Development | Profile | |
| Melissa Gaines | Senior Operations | Profile | |
| Mark White | Independent Director | Profile | |
| William CPA | Chief Officer | Profile | |
| Hilda Maibach | Senior Statistics | Profile |
Already Invested in Annovis Bio?
The danger of trading Annovis Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Annovis Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Annovis Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Annovis Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.